Summary
Enprofylline, a new bronchodilating drug, was given i.v. at 1.0 mg/kg to 7 healthy subjects and to 14 patients with differing degrees of chronic renal insufficiency. Plasma and urine concentrations of unchanged drug were followed by HPLC. In the patients the plasma half-life was prolonged and the total and renal clearances were reduced in direct proportion to the degree of renal insufficiency as determined by creatinine clearance. The unbound fraction of enprofylline in plasma increased from 55% in the healthy subjects to 66% in the group of patients with the highest degree of renal impairment. The volume of distribution terms, Vβ and Vss, both tended to decrease with decreasing creatinine clearance. When the volume term calculations were based on the unbound drug level in plasma, this tendency was enhanced. Side-effects were noted in 4 subjects, and to some extent were related to the plasma level of the drug.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Antal EJ, Kramer PA, Mercik SA, Chapron DJ, Lawson IR (1981) Theophylline pharmacokinetics in advanced age. Br J Clin Pharmacol 12:637–645
Benet LZ, Galeazzi RL (1979) Noncompartmental determination of the steady state-volume of distribution. J Pharm Sci 68:1071–1074
Borgå O (1979) Drug binding in uremia. In: Tillement JP (ed) Advances in pharmacology and therapeutics, vol 7. Biochemical clinical pharmacology, Pergamon Press, Oxford New York, pp 143–152
Borgå O, Andersson K-E, Edholm L-E, Fagerström P-O, Lunell E, Persson CGA (1983). Enprofylline kinetics in healthy subjects after single doses. Clin Pharmacol Ther 34:799–804
Buss D, Leopold D, Smith AP, Routledge PA (1983) Determinants of the plasma protein binding of theophylline in health. Br J Clin Pharmacol 15:143P
Ehrnebo M, Agurell S, Jalling B, Boréus L-O (1971) Age differences in drug binding by plasma proteins: studies on human fetuses, neonates and adults. Eur J Clin Pharmacol 3:189–193
Gibaldi M, McNamara PJ (1978) Apparent volumes of distribution and drug binding to plasma protein and tissues. Eur J Clin Pharmacol 13:373–378
Jenne JW, Nagazawa HT, Thompson RD (1976) Relationships of urinary metabolites of theophylline to serum theophylline levels. Clin Pharmacol Ther 19:375–381
Jusko WJ, Chiang ST (1982) Distribution volume related to body weight and protein binding. J Pharm Sci 71:469–470
Larsson R, Erlanson P, Bodemar G, Norlander B, Fransson L, Strouth L (1982) Pharmacokinetics of cimetidine and its sulphoxide metabolite during haemodialysis. Eur J Clin Pharmacol 21:325–330
Lunell E, Svedmyr N, Andersson K-E, Persson CGA (1982) Effects of enprofylline, a xanthine lacking adenosine receptor antagonism, in patients with chronic obstructive lung disease. Eur J Clin Pharmacol 22:395–402
Maddocks JL, Wake CJ, Harber MJ (1975) The plasma half-life of antipyrine in chronic uremic and normal subjects. Br J Clin Pharmacol 2:339–343
Odar-Cederlöf I, Borgå O (1976) Impaired plasma protein binding of phenytoin in uremia and displacement effect of salicylic acid. Clin Pharmacol Ther 20:36–47
Persson CGA, Andersson K-E (1977) Respiratory and cardiovascular effects of 3-methylxanthine, a metabolite of theophylline. Acta Pharmacol Toxicol 40:529–536
Persson CGA, Erjefält I, Edholm L-E, Karlsson J-A, Lamm C-J (1982) Tracheal relaxant and cardiostimulant actions of xanthines can be differentiated from diuretic and CNS-stimulant effects. Role of adenosine antagonism? Life Sci 31:2673–2681
Persson CGA, Erjefält I, Karlsson J-A (1981) Adenosine antagonism, a less desirable characteristic of xanthine asthma drugs? Acta Pharmacol Toxicol 49:317–320
Persson CGA, Kjellin G (1981) Enprofylline, a principally new antiasthmatic xanthine. Acta Pharmacol Toxicol 49:313–316
Reidenberg MM (1976) The binding of drugs to plasma proteins from patients with poor renal function. Clin Pharmacokinet 1:121–125
Sjöholm I, Kober A, Odar-Cederlöf I, Borgå O (1976) Protein binding of drugs in uremic and normal serum: the role of endogenous binding inhibitors. Biochem Pharmacol 25:1205–1213
Smith DE, Gambertoglio JG, Vincenti F, Benet LZ (1981) Furosemide kinetics and dynamics after kidney transplant. Clin Pharmacol Ther 30:105–113
Tegnér K, Borgå O, Svensson J (1983) Protein binding of enprofylline. Eur J Clin Pharmacol 25:703–708
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lunell, E., Borgå, O. & Larsson, R. Pharmacokinetics of enprofylline in patients with impaired renal function after a single intravenous dose. Eur J Clin Pharmacol 26, 87–93 (1984). https://doi.org/10.1007/BF00546714
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00546714